Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-23 19:43 | 2026-04-21 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | BUY | $0.33 | 72,912 | $24,061 | 133,574 |
| 2026-04-23 01:44 | 2026-04-22 | NSRX | Nasus Pharma Ltd | Teleman Dan Benjamin | Director, Officer | BUY | $3.76 | 2,900 | $10,904 | 156,991 |
| 2026-04-23 00:03 | 2026-04-20 | PCRX | Pacira BioSciences, Inc. | Cross Shawn | Officer | OPT+S | $25.09 | 12,059 | $302,599 | 105,341 |
| 2026-04-22 22:27 | 2026-04-20 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Director | SELL | $19.75 | 834,302 | $16,477,381 | 1,285,704 |
| 2026-04-22 22:27 | 2026-04-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $29.59 | 200,000 | $5,918,000 | 1,647,546 |
| 2026-04-22 22:09 | 2026-04-06 | RDHL | RedHill Biopharma Ltd. | Raday Gilead | Officer | OPT+S | $0.00 | 15,740,000 | $1,574 | 261,060,000 |
| 2026-04-22 21:55 | 2026-04-20 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $6.14 | 65,663 | $403,085 | 297,066 |
| 2026-04-22 21:32 | 2026-04-20 | ATAI | AtaiBeckley Inc. | Craig Kevin James | Officer | OPT+S | $5.00 | 42,579 | $212,895 | 8,437 |
| 2026-04-22 21:07 | 2026-04-20 | TRAX | First Tracks Biotherapeutics, Inc. | EcoR1 Capital, LLC | 10% owner | SELL | $13.81 | 4,705,575 | $64,999,990 | 3,174,519 |
| 2026-04-22 20:53 | 2026-04-21 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | Officer | OPT+S | $23.00 | 9,200 | $211,614 | 145,355 |
| 2026-04-22 20:30 | 2026-04-21 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $570.42 | 9,500 | $5,419,006 | 40,513 |
| 2026-04-22 20:15 | 2026-04-21 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $166.00 | 1,000 | $166,000 | 11,666 |
| 2026-04-22 20:15 | 2026-04-20 | KLRA | Kailera Therapeutics, Inc. | RTW INVESTMENTS, LP | 10% owner | BUY | $16.00 | 500,000 | $8,000,000 | 10,776,820 |
| 2026-04-22 20:03 | 2026-04-21 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | Officer | SELL | $8.94 | 449 | $4,014 | 56,290 |
| 2026-04-22 18:59 | 2026-04-21 | ONCO | Onconetix, Inc. | HRT FINANCIAL LP | 10% owner | SELL | $0.69 | 49,710 | $34,300 | 33,649 |
| 2026-04-22 00:40 | 2026-04-17 | SION | Sionna Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director | SELL | $44.67 | 55,345 | $2,472,344 | 2,964,774 |
| 2026-04-22 00:40 | 2026-04-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Officer | OPT+S | $47.67 | 5,000 | $238,353 | 25,000 |
| 2026-04-22 00:42 | 2026-04-17 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Director | SELL | $44.67 | 55,345 | $2,472,344 | 2,964,774 |
| 2026-04-21 23:36 | 2026-04-17 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% owner | SELL | $40.32 | 426,005 | $17,175,244 | 6,709,228 |
| 2026-04-21 22:59 | 2026-04-17 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $31.33 | 416 | $13,033 | 69,792 |
| 2026-04-21 21:28 | 2026-04-20 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $163.59 | 1,000 | $163,595 | 12,666 |
| 2026-04-21 20:55 | 2026-04-17 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Officer | SELL | $39.99 | 20,225 | $808,844 | 246,426 |
| 2026-04-21 20:58 | 2026-04-20 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer | SELL | $105.47 | 1,750 | $184,573 | 59,003 |
| 2026-04-21 20:35 | 2026-04-17 | NUVB | Nuvation Bio Inc. | Wentworth Kerry | Officer | OPT+S | $5.01 | 36,750 | $184,279 | 53,000 |
| 2026-04-21 20:22 | 2026-04-21 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $65.69 | 3,500 | $229,915 | 153,902 |
| 2026-04-21 20:30 | 2026-04-17 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | SELL | $40.60 | 18,839 | $764,956 | 1,423,095 |
| 2026-04-21 20:34 | 2026-04-17 | NUVB | Nuvation Bio Inc. | Liu Dongfang | Officer | OPT+S | $5.02 | 50,000 | $251,000 | 18,000 |
| 2026-04-21 20:15 | 2026-04-17 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Director | SELL | $20.21 | 337,248 | $6,815,175 | 4,207,525 |
| 2026-04-21 19:41 | 2026-04-17 | ONCO | Onconetix, Inc. | HRT FINANCIAL LP | 10% owner | BUY | $0.73 | 34,636 | $25,284 | 177,821 |
| 2026-04-21 19:41 | 2026-04-16 | ONCO | Onconetix, Inc. | HRT FINANCIAL LP | 10% owner | SELL | $0.74 | 148,329 | $110,164 | 83,359 |
| 2026-04-21 11:41 | 2026-04-20 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $577.86 | 10,000 | $5,778,607 | 18,876 |
| 2026-04-21 11:41 | 2026-04-20 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $577.83 | 9,500 | $5,489,424 | 40,513 |
| 2026-04-20 23:40 | 2026-04-17 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $20.22 | 9,550 | $193,066 | 462,577 |
| 2026-04-20 23:40 | 2026-04-17 | KALV | KalVista Pharmaceuticals, Inc. | Piekos Brian | Officer | OPT+S | $20.22 | 1,862 | $37,643 | 18,150 |
| 2026-04-20 23:41 | 2026-04-17 | KALV | KalVista Pharmaceuticals, Inc. | Sweeny Nicole | Officer | OPT+S | $20.22 | 1,862 | $37,643 | 51,391 |
| 2026-04-20 23:42 | 2026-04-17 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $20.22 | 2,686 | $54,301 | 142,547 |
| 2026-04-20 23:27 | 2026-04-20 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | Director, Officer | OPT+S | $23.61 | 15,000 | $354,146 | 362,152 |
| 2026-04-20 22:27 | 2026-04-16 | ROIV | Roivant Sciences Ltd. | Gline Matthew | Director, Officer | SELL | $29.16 | 289,774 | $8,449,810 | 16,736,116 |
| 2026-04-20 22:08 | 2026-04-20 | KLRA | Kailera Therapeutics, Inc. | Koppel Adam | Director, 10% owner | BUY | $16.00 | 1,562,500 | $25,000,000 | 22,583,268 |
| 2026-04-20 22:10 | 2026-04-20 | KLRA | Kailera Therapeutics, Inc. | BAIN CAPITAL INVESTORS LLC | 10% owner | BUY | $16.00 | 8,398,438 | $134,375,008 | 26,255,581 |
| 2026-04-20 22:00 | 2026-04-20 | KLRA | Kailera Therapeutics, Inc. | Kaplan Andrew T. | Director, 10% owner | BUY | $16.00 | 8,398,438 | $134,375,008 | 26,255,581 |
| 2026-04-20 22:01 | 2026-04-20 | KLRA | Kailera Therapeutics, Inc. | Bain Capital Life Sciences Investors, LLC | 10% owner | BUY | $16.00 | 1,562,500 | $25,000,000 | 22,583,268 |
| 2026-04-20 20:38 | 2026-04-17 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $586.66 | 9,500 | $5,573,223 | 40,513 |
| 2026-04-20 20:06 | 2026-04-16 | MIST | Milestone Pharmaceuticals Inc. | Oliveto Joseph | Director, Officer | SELL | $2.26 | 36,500 | $82,490 | 446,244 |
| 2026-04-20 20:15 | 2026-04-16 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $160.38 | 1,000 | $160,381 | 14,666 |
| 2026-04-20 20:15 | 2026-04-17 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $161.63 | 1,000 | $161,630 | 13,666 |
| 2026-04-20 19:00 | 2026-04-16 | PHVS | Pharvaris N.V. | Modig Berndt | Director, Officer | SELL | $28.60 | 2,292 | $65,559 | 139,792 |
| 2026-04-17 20:05 | 2026-04-15 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Director | SELL | $20.35 | 99,613 | $2,027,154 | 4,544,773 |
| 2026-04-17 20:05 | 2026-04-15 | MPLT | MapLight Therapeutics, Inc. | Setia Vishwas | Officer | SELL | $26.89 | 2,922 | $78,572 | 392,627 |
| 2026-04-17 20:05 | 2026-04-15 | MPLT | MapLight Therapeutics, Inc. | Kreitzer Anatol | Officer | SELL | $26.61 | 3,316 | $88,239 | 256,612 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.